Abstract
Despite the fact that anti-TNF alpha antibodies are well-tolerated and highly effective in Crohns disease 25% to 40% of patients who initially benefited from the treatment are developing intolerable adverse events or are losing their response during maintenance therapy. The molecular mechanisms of loss of response are not fully understood, but clinicians face this clinical problem. The Aim of this paper is to review the clinical strategies to face loss of response to anti- TNF alpha antibodies in Crohns disease.
Current Drug Targets
Title: “How to Manage Loss of Response to Anti-TNF in Crohns Disease?”
Volume: 11 Issue: 2
Author(s): Walter Reinisch
Affiliation:
Abstract: Despite the fact that anti-TNF alpha antibodies are well-tolerated and highly effective in Crohns disease 25% to 40% of patients who initially benefited from the treatment are developing intolerable adverse events or are losing their response during maintenance therapy. The molecular mechanisms of loss of response are not fully understood, but clinicians face this clinical problem. The Aim of this paper is to review the clinical strategies to face loss of response to anti- TNF alpha antibodies in Crohns disease.
Export Options
About this article
Cite this article as:
Reinisch Walter, “How to Manage Loss of Response to Anti-TNF in Crohns Disease?”, Current Drug Targets 2010; 11 (2) . https://dx.doi.org/10.2174/138945010790309894
DOI https://dx.doi.org/10.2174/138945010790309894 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Innate Immunity in Alzheimer’s Disease: A Complex Affair
CNS & Neurological Disorders - Drug Targets Adipose Derived Stem Cells for Musculoskeletal Regeneration: Recent Patents and Future Perspectives
Recent Patents on Regenerative Medicine Crucial Protein Based Drug Targets and Potential Inhibitors for Osteoporosis: New Hope and Possibilities
Current Drug Targets OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) Editorial
Current Rheumatology Reviews Clinical Experience with Thalidomide and Lenalidomide in Multiple Myeloma
Current Cancer Drug Targets Structure- and Fragment-Based Approaches to Protease Inhibition
Current Topics in Medicinal Chemistry A QSAR Study on a Series of Pyrrole Derivatives Acting as Lymphocyte- Specific Kinase (Lck) Inhibitors
Medicinal Chemistry Clinical Review of COVID-19; Pathogenesis, Diagnosis, and Management
Current Pharmaceutical Design Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design Antioxidants in Treating Pathologies Involving Oxidative Damage: An Update on Medicinal Chemistry and Biological Activity of Stobadine and Related Pyridoindoles
Current Medicinal Chemistry Differential Action of Phytochemicals on Platelet Apoptosis: A Biological Overview
Current Medicinal Chemistry Editorial: [Hot Topic: Chromogranin A at the Crossroads of Health and Disease]
Current Medicinal Chemistry Tumor Necrosis Factor Blockade for Treatment of Inflammatory Bowel Disease: Efficacy and Safety
Current Molecular Pharmacology Functional Components from Nature-Derived Drugs for the Treatment of Rheumatoid Arthritis
Current Drug Targets Role of Pro-inflammatory Cytokines in Regulation of Skeletal Muscle Metabolism: A Systematic Review
Current Medicinal Chemistry Editorial [ UCTD and Unfinished Business ]
Current Rheumatology Reviews Natural Killer T Cells and Autoimmune Disease
Current Molecular Medicine Editorial from Guest Editor (Thematic Issue: Connective Tissue Disease-Associated Interstitial Lung Disease)
Current Respiratory Medicine Reviews Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry